IMW 2021 | Monoclonal antibodies and ADCs for myeloma
Jakub Radocha, PhD, of Charles University, Faculty of Medicine in Hradec Kralove, Prague, Czech Republic, discusses the impact of monoclonal antibodies and antibody-drug conjugates (ADCs) on the treatment landscape of myeloma, and suggests areas that need further research to optimize the use of these drugs. The addition of monoclonal antibodies to standard treatments has been shown to be beneficial for patients with myeloma; however, some unanswered questions remain. Dr Radocha suggests that novel ADCs, such as belantamab mafodotin, could be developed for use when the frontline treatment fails, but highlights the challenges of toxicity which limit the use of ADCs in myeloma. Whilst these drugs could have benefits for patients with myeloma, they still have limitations which need to be resolved before their use can be optimized. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Jakub Radocha, PhD, is a medical advisory board member for BMS, Janssen, GSK, Amgen and Sanofi; and has received travel expense reimbursement from BMS, Amgen and Sanofi.
